We also describe how the capacity of silibinin to attenuate a hyperactive TGFβ/SMAD signaling axis can overcome EMT-driven resistance to multiple-generation ALK–TKIs in ALK-rearranged NSCLC cells. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.